Culture Biosciences, a company involved in upstream bioprocess development and Cytiva, a company that advances and accelerates the development of therapeutics, entered into a collaboration to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Cytiva and Culture Biosciences aim to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments.

As the first step in this new collaboration, Cytiva’s Bioreactor Scaler tool now includes Culture’s 250 mL bioreactor. The Bioreactor Scaler tool enables seamless scaling between development and manufacturing. Scientists can identify scale-up or scale-down process control parameters by entering in their existing process details and cell line characteristics. The tool helps to de-risk scaling activities and ensure product quality. Teams can collaborate virtually from anywhere.

Culture Biosciences’  upstream bioprocess development platform allows customers to design and monitor their experiments, collaborate on projects, and access and analyze data on a fully integrated platform that combines:

• 250mL bioreactors and 5L bioreactors, each with single-use vessels for mammalian cell lines or microbial fermentation. The 250mL reactors are mounted in mobile cart modules of four units.
• Dedicated cloud-based software to design and monitor experiments remotely, and to integrate and analyze data in one place. Remote, hybrid or multi-location teams can collaborate virtually on this platform.
• A suite of tools for process design and data analysis including a dynamic data analysis suite that enables rapid analysis and understanding of process and offline analytical data.

“Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and data produced from our collaborative platform will help them predict performance at the next level, whether it be clinical or commercial scale,” said Nicolas Pivet, head of automation, controls, digital and learning, Cytiva. “You can accelerate the therapeutic process development.”

“We are thrilled by the prospect to advance upstream bioprocess development with a global leader in the development, manufacturing and delivery of therapeutics,” said Will Patrick, CEO of Culture Biosciences. “Digital technologies have greatly advanced other manufacturing sectors in recent years. We look forward to our work with Cytiva to bring similar innovation to upstream bioprocess development, for the benefit of both our customers and their patients.”